-
1.发明授权Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof 有权结合蛋白质，包括特异性结合CD154的抗体，抗体衍生物和抗体片段及其用途公开(公告)号：US09321840B2
公开(公告)日：2016-04-26
申请号：US14309118
申请日：2014-06-19
Applicant: UCB PHARMA S.A. , BIOGEN IDEC MA INC.
Inventor： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。
-
公开(公告)号：US20130189713A1
公开(公告)日：2013-07-25
申请号：US13776098
申请日：2013-02-25
Applicant: BIOGEN IDEC MA INC.
Inventor： Yen-ming Hsu , Lihe Su
IPC: G01N33/68
CPC classification number: G01N33/6863 , G01N33/86
Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
Abstract translation: 本发明提供了确定血小板聚集的方法，在给予CD40L结合部分时确定凝血敏感性的方法，以及与其相关的试剂盒。
-
公开(公告)号：US09297810B2
公开(公告)日：2016-03-29
申请号：US13776098
申请日：2013-02-25
Applicant: BIOGEN IDEC MA INC.
Inventor： Yen-ming Hsu , Lihe Su
CPC classification number: G01N33/6863 , G01N33/86
Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
Abstract translation: 本发明提供了确定血小板聚集的方法，在给予CD40L结合部分时确定凝血敏感性的方法，以及与其相关的试剂盒。
-
4.发明授权Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof 有权结合蛋白质，包括特异性结合CD154的抗体，抗体衍生物和抗体片段及其用途公开(公告)号：US08784823B2
公开(公告)日：2014-07-22
申请号：US13656922
申请日：2012-10-22
Applicant: UCB Pharma S.A. , Biogen Idec MA Inc.
Inventor： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC: C07K16/28 , A61K39/395 , A61P19/02 , A61P19/04
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。
-
-
-
Search Results
4
records
(took 0.015 seconds)
